Transcript May 2015 Cancer Committee Meeting Cancer Liaison Physician Report

Cancer Committee Meeting
May 11, 2015
Cancer Liaison Physician Report
Karen Lisa Smith MD MPH
5 year survival for breast
cancer patients at Sibley
Stage
Enter
0 Year
1 Year
2 Year
3 Year
4 Year
5 Year
5 Year
95% CI
Stage 0
407
100.0
100.0
99.8
98.7
98.2
97.4
95.8-99.0
Stage I
650
100.0
99.5
98.8
97.7
96.2
95.3
93.7-97.0
Stage II
476
100.0
99.4
97.9
95.2
93.5
92.1
89.6-94.6
Stage III
137
100.0
100.0
92.6
91.1
88.0
81.6
74.9-88.3
Stage IV
3
Insufficient cases (n<30)
Unknown
61
100.0
96.7
91.5
86.2
80.7
70.5-91.0
96.7
5 year survival for breast
cancer patients at all sites in
the NCDB
Stage
Enter
0 Year
1 Year
2 Year
3 Year
4 Year
5 Year
5 Year
95% CI
Stage 0
136,242
100.0
99.5
98.7
97.7
96.6
95.3
95.2-95.4
Stage I
272,101
100.0
99.2
97.8
96.0
94.1
92.0
91.9-92.1
Stage II
196,351
100.0
98.3
95.4
92.0
88.7
85.6
85.4-85.7
Stage III
74,610
100.0
95.3
87.2
79.6
73.2
67.9
67.5-68.2
Stage IV
25,972
100.0
68.5
51.3
38.8
29.6
23.2
22.7-23.7
Not
Applicabl
e
513
100.0
87.7
75.5
70.4
65.7
62.2
57.8-66.6
Breast cancer 5 year survival
• Sibley outcomes comparable to or better
than national NCDB outcomes
Number of new prostate
cancer patients at Sibley in
comparison to other DC
hospitals
Diagnosis Year of Prostate Cancer Diagnosed in
2010,2011,2012
Sibley Memorial Hospital, Washington DC
vs. All Types Hospitals in State of District of Columbia
All Diagnosed Cases - Data from 7 Hospitals
#
Diagnosis Year My
(N)
Oth. (N) My (%)
Oth. (%)
1.
2010
157
1195
36.6%
39.43%
2.
2011
165
1054
38.46%
34.77%
3.
2012
107
782
24.94%
25.8%
429
3031
100%
100%
Col. TOTAL
Prostate cancer cases at Sibley
• Numbers are low
• What can we do to capture more of the
regional market?
CP3R Measures for Breast
Cancer for Sibley compared to
all COC Approved Programs
(2012)
Measure
Sibley
All COC approved
programs
*Breast Conserving Surgery for Stage 0-2
50%
63%
Image or palpation guided core biopsy or
FNA to establish diagnosis
85%
89%
*Tamoxifen or 3rd generation AI within 1 yar
of diagnosis for stage 1B-3 Hormone
receptor positive breast cancer
3.4%
90%
*RT within in year after mastectomy if >=4+
nodes
46.2%
87%
*RT within one year after BCS for patients < 68%
70
91%
*Combination chemotherapy considered or
given within 120 days of diagnosis if < 70
and hormone receptor negative and stage
1B-3
92%
36%
* = Sibley rate below mean of COC approved programs
Breast CP3R data
• Sibley scores are low in many areas
• Likely represents inaccurate data capture
and not poor adherence with these
standard of care measures
• How can we improve data capture for
these measures?
• Note: inadequate numbers to
meaningfully review CP3R data from 2012
for other sites with measures (gastric,
colon, lung, rectum, cervix)
Questions?